RPR-200765A Mesylayte - CAS 218162-38-0

RPR-200765A is a potent and selective inhibitor of p38 MAP kinase (IC50 = 50 nM) . It inhibits LPS-stimulated TNFalpha release both in vitro, from human monocytes (EC50 = 110 nM), and in vivo in Balb/c mice (ED50 = 6 mg/kg) . At oral doses between 10 and 30 mg/kg/day it reduces the incidence and progression in the rat streptococcal cell wall (SCW) arthritis model when administered in either prophylactic or therapeutic dosing regimens. The compound, which is a mesylate salt and exists as a stable monohydrate, shows good oral bioavailabiltiy (F = 50% in the rat) and excellent chemical stability. The data from the SCW disease model suggests that RPR200765A could exhibit a profile of disease modifying activity in rheumatoid arthritis (RA) patients which is not observed with current drug therapies.

Others

Others

218124

C24H25FN4O4

452.48

CS(O)(=O)=O.C[C@@]1(CO[C@@H](OC1)c1nc(c([nH]1)-c1ccncc1)-c1ccc(F)cc1)C(=O)N1CCOCC1

-20°C

Ice Packs

Small Compound